Spectrum of Movement disorders, Imaging findings in SSPE and response to therapy – A prospective cohort study
Objective: We present the clinical profile, imaging, treatment trends and outcomes of a cohort SSPE patients who presented to our Institute with movement disorders. Background:…Incorporating the Voice of the Patient and Caregiver into a Multiple System Atrophy (MSA) clinical trial
Objective: To understand patient and caregiver preferences and perceptions of a proposed clinical trial design for an interventional drug targeting Multiple System Atrophy. Background: Stakeholders…Patient Characteristics and Real-World Use of Botulinum Toxins for Treatment of Chronic Sialorrhea
Objective: We aimed to describe the demographics, clinical characteristics, and treatment patterns among patients with evidence of chronic sialorrhea. Background: Patients with neurological impairment may…A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.
Objective: Assess safety and immunogenicity of UB-312 in a phase 1b trial in Multiple System atrophy (MSA) or Parkinson’s disease (PD). Background: Abnormal deposition of…Clinical and Neurophysiological Response of Different Protocols of Non-Invasive Spinal Neuromodulation in Anti-Gad Positive Stiff Person Syndrome: A Case Report
Objective: To evaluate the effects of non-invasive neuromodulation techniques transpinal magnetic stimulation (TsMS) and transcutaneous electrical stimulation (TENS) in Stiff person syndrome (SPS). Background: SPS…Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide
Objective: An innovative, multi-study Phase 3 program to definitively assess safety and efficacy of ulixacaltamide in essential tremor (ET). Background: Phase 2 studies of ulixacaltamide,…Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial – ISRCTN99462035.
Objective: The NORAPS Phase II clinical trial seeks to demonstrate safety, tolerability and efficacy of atomoxetine in Progressive Supranuclear Palsy (PSP). Background: PSP is a…ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)
Objective: Here we describe ORION, a phase 3 trial assessing efficacy and safety of AMX0035 in progressive supranuclear palsy (PSP). Background: PSP is a rare,…SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor
Objective: KINETIC2 is a multicenter, randomized, placebo-controlled, dose-response Ph2b study evaluating SAGE-324/BIIB124 for treatment of essential tremor (ET). Background: ET is a common movement disorder1,2…Gathering Prodromal Participant Perspective on Receiving Personal Research Information
Objective: To understand perceptions and expectations of people with prodromal Parkinson’s disease (PD) around receiving personal research information. Background: There is limited information on the…
- « Previous Page
- 1
- …
- 395
- 396
- 397
- 398
- 399
- …
- 1942
- Next Page »